Joerg Herrmann1, Charles Loprinzi2, Kathryn Ruddy2. 1. Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. herrmann.joerg@mayo.edu. 2. Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Abstract
PURPOSE OF REVIEW: This review aims to outline the general principles of how to build a cardio-onco-hematology clinic, acknowledging that there are diverse practices ranging from private community settings to academic hospitals and each practice environment has to build its own program. RECENT FINDINGS: The refinement of regimens and introduction of molecularly directed therapies have substantially increased survival rates for patients with cancer. In fact, a number of previous imminently fatal malignant disease processes have been turned into chronic diseases, such that patients now live with certain incurable cancers as they do, for instance, with rheumatoid arthritis. Improved cure rates and longer survivals have raised side effects of cancer treatments to a completely new level of significance. Cardiovascular toxicities are of particular concern given their impact on morbidity and mortality. In most extreme cases, patients might be cured from cancer but remain debilitated or die prematurely because of cardiovascular disease. Furthermore, not an insignificant proportion of cancer patients start cancer therapy with cardiovascular risk factors and diseases at baseline. With the aging of the population, this "joint venture" is only expected to increase with important implications for the management of cancer patients. Given the need for familiarity with both, cancer and cardiovascular diseases and their ever-evolving start-of-the-art therapy and interaction potential, specialized efforts have been invoked, which may collectively be termed "onco-cardiology," "cardio-oncology," or "cardio-onco-hematology." Herein, we provide recommendations for the creation and optimization of any such programmatic efforts.
PURPOSE OF REVIEW: This review aims to outline the general principles of how to build a cardio-onco-hematology clinic, acknowledging that there are diverse practices ranging from private community settings to academic hospitals and each practice environment has to build its own program. RECENT FINDINGS: The refinement of regimens and introduction of molecularly directed therapies have substantially increased survival rates for patients with cancer. In fact, a number of previous imminently fatal malignant disease processes have been turned into chronic diseases, such that patients now live with certain incurable cancers as they do, for instance, with rheumatoid arthritis. Improved cure rates and longer survivals have raised side effects of cancer treatments to a completely new level of significance. Cardiovascular toxicities are of particular concern given their impact on morbidity and mortality. In most extreme cases, patients might be cured from cancer but remain debilitated or die prematurely because of cardiovascular disease. Furthermore, not an insignificant proportion of cancerpatients start cancer therapy with cardiovascular risk factors and diseases at baseline. With the aging of the population, this "joint venture" is only expected to increase with important implications for the management of cancerpatients. Given the need for familiarity with both, cancer and cardiovascular diseases and their ever-evolving start-of-the-art therapy and interaction potential, specialized efforts have been invoked, which may collectively be termed "onco-cardiology," "cardio-oncology," or "cardio-onco-hematology." Herein, we provide recommendations for the creation and optimization of any such programmatic efforts.
Entities:
Keywords:
Cardio-oncology clinics; Cardio-oncology programs; Cardiotoxicity; Multidisciplinary practice
Authors: Geoffrey J Yoon; Melinda L Telli; David P Kao; Kelly Y Matsuda; Robert W Carlson; Ronald M Witteles Journal: J Am Coll Cardiol Date: 2010-11-09 Impact factor: 24.094
Authors: Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli Journal: Mayo Clin Proc Date: 2014-09 Impact factor: 7.616
Authors: Adriana Albini; Giuseppina Pennesi; Francesco Donatelli; Rosaria Cammarota; Silvio De Flora; Douglas M Noonan Journal: J Natl Cancer Inst Date: 2009-12-10 Impact factor: 13.506
Authors: Sherry-Ann Brown; Eric H Yang; Mary Branch; Craig Beavers; Anne Blaes; Michael G Fradley; Richard K Cheng Journal: Heart Fail Clin Date: 2022-07 Impact factor: 2.828